CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chu, Po Yin ^a   Walder, Ken ^b   Horlock, Duncan ^a   Williams, David ^a   Nelson, Erin ^a   Byrne, Melissa ^a   Jandeleit Dahm, Karin ^c   Zimmet, Paul ^c   Kaye, David M ^a  

^a Baker IDI Heart Research Institute   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CANDESARTAN HEXETIL; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GLIAL FIBRILLARY ACIDIC PROTEIN; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; HETEROCYCLIC COMPOUND; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL MOTILITY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE FIBROSIS; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETIC CARDIOMYOPATHIES; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART VENTRICLE; HEMODYNAMICS; HUMAN; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BONE MARROW TRANSPLANTATION; CHEMOKINE CXCL12; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FIBROSIS; HEART VENTRICLES; HEMODYNAMICS; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; MICE, TRANSGENIC; MYOFIBROBLASTS; RECEPTORS, CXCR4; TETRAZOLES;

EID: 84941902143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133616     Document Type: Article

References (39)

1. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: A 21st century challenge. The lancet Diabetes & endocrinology. 2014; 2(1):56-64. Epub 2014/03/14. doi: 10.1016/S2213-8587(13)70112-8 PMID: 24622669.
2. Alberti KG, Zimmet P. Global burden of disease-where does diabetes mellitus fit in? Nature reviews Endocrinology. 2013; 9(5):258-60. Epub 2013/03/13. doi: 10.1038/nrendo.2013.54 PMID: 23478328.
3. Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin. 2012; 8(4):619-31. Epub 2012/09/25. doi: 10.1016/j.hfc.2012.06.007 PMID: 22999244; PubMed Central PMCID: PMC3457018.
4. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22):2668-73. Epub 2001/06/08. PMID: 11390335.
5. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in Heart Failure: Prevalence and Impact on Outcome in the Population. American Journal of Medicine. 2006; 119 (7): 591-9. PMID: 16828631.
6. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The Strong Heart Study. Circulation. 2000; 101(19):2271-6. PMID: 10811594.
7. Aneja A, Tang WHW, Bansilal S, Garcia MJ, Farkouh ME. Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. American Journal of Medicine. 2008; 121 (9):748-57. doi: 10.1016/j.amjmed.2008.03.046 PMID: 18724960.
8. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin A1c with incident heart failure among people without diabetes: The atherosclerosis risk in communities study. Diabetes. 2010; 59(8):2020-6. doi: 10.2337/db10-0165 PMID: 20484138.
9. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging.
10. Dhingra R, Vasan RS. Diabetes and the risk of heart failure. Heart Fail Clin. 2012; 8(1):125-33. Epub 2011/11/24. doi: 10.1016/j.hfc.2011.08.008 PMID: 22108732; PubMed Central PMCID: PMC3223386.
11. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JMO, Warnica JW, et al. Predictors of Late Development of Heart Failure in Stable Survivors of Myocardial Infarction: The CARE Study. Journal of the American College of Cardiology. 2003; 42(8):1446-53. PMID: 14563590.
12. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. American Journal of Cardiology. 1988; 62(10 PART I):665-9. PMID: 3421162.
13. Konig A, Bode C, Bugger H. Diabetes mellitus and myocardial mitochondrial dysfunction: bench to bedside. Heart Fail Clin. 2012; 8(4):551-61. Epub 2012/09/25. doi: 10.1016/j.hfc.2012.06.001 PMID: 22999239.
14. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, et al. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol. 2002; 282(1):H138-48. Epub 2001/12/19. PMID: 11748057.
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. Epub 2006/12/15. doi: 10.1038/nature05485 PMID: 17167474.
16. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation. 2007; 116(10):1170-5. PMID: 17698735.
17. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007; 204(10):2449- 60. Epub 2007/09/19. doi: jem.20070657 [pii] doi: 10.1084/jem.20070657 PMID: 17875676; PubMed Central PMCID: PMC2118469.
18. Chu PY, Zatta A, Kiriazis H, Chin-Dusting J, Du XJ, Marshall T, et al. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail. 2011; 4(5):651-8. Epub 2011/06/21. doi: 10.1161/CIRCHEARTFAILURE.110.960831 PMID: 21685249.
19. Walder KR, Fahey RP, Morton GJ, Zimmet PZ, Collier GR. Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). International journal of experimental diabetes research. 2000; 1(3):177-84. Epub 2001/07/27. PMID: 11467408; PubMed Central PMCID: PMC2477729.
20. Kaiser N, Cerasi E, Leibowitz G. Diet-induced diabetes in the sand rat (Psammomys obesus). Methods Mol Biol. 2012; 933:89-102. Epub 2012/08/16. doi: 10.1007/978-1-62703-068-7-7 PMID: 22893403.
21. Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, et al. Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009; 78(8):993- 1000. Epub 2009/06/23. S0006-2952(09)00479-1 [pii] doi: 10.1016/j.bcp.2009.06.010 PMID: 19540208.
22. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: A scientific statement from the American Heart Association Councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008; 117(19):2544-65. doi: 10.1161/CIRCULATIONAHA.107.188965 PMID: 18391114.
23. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. Journal of the American Medical Association. 1979; 241(19):2035-8. PMID: 430798.
24. De Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive Journal of Hypertension. 2010; 28(2):353-60. doi: 10.1097/HJH.0b013e3283331169 PMID: 1984418.
25. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart Failure Prevalence, Incidence, and Mortality in the Elderly with Diabetes. Diabetes Care. 2004; 27(3):699-703. PMID: 14988288.
26. Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Archives of Internal Medicine. 2004; 164(20):2273-9. PMID: 15534166.
27. Lindman BR, Arnold SV, Madrazo JA, Zajarias A, Johnson SN, Pérez JE, et al. The Adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circulation: Heart Failure. 2011; 4(3):286-92. doi: 10.1161/CIRCHEARTFAILURE.110.960039 PMID: 21357546.
28. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine. 1990; 322(22):1561-6. PMID: 2139921.
29. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. Am J Cardiol. 2001; 87(2):224-5, A8-9. PMID: 11152847.
30. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care. 2004; 27(8):1879-84. PMID: 15277411.
31. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The cardiovascular health study. Journal of the American College of Cardiology. 2001; 37(4):1042-8. PMID: 11263606.
32. Shivalkar B, Dhondt D, Goovaerts I, Van Gaal L, Bartunek J, Van Crombrugge P, et al. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. American Journal of Cardiology. 2006; 97 (1):77-82. PMID: 16377288.
33. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37(2):1253-62. Epub 2004/09/24. 00126334-200410010-00005 [pii]. PMID: 15385732.
34. Jie W, Wang X, Zhang Y, Guo J, Kuang D, Zhu P, et al. SDF-1alpha/CXCR4 axis is involved in glucose- potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. International journal of experimental pathology. 2010; 91(5):436-44. Epub 2010/07/01. doi: 10.1111/j.1365-2613.2010. 00720.x PMID: 20586815; PubMed Central PMCID: PMC3003841.
35. Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T, et al. Bone Marrow-Derived Cells Contribute to Fibrosis in the Chronically Failing Heart. Am J Pathol. 2010; 176:1735-42. Epub 2010/02/13. ajpath.2010.090574 [pii] doi: 10.2353/ajpath.2010.090574 PMID: 20150435.
36. Amador CA, Barrientos V, Pena J, Herrada AA, Gonzalez M, Valdes S, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension. 2014; 63(4):797-803. Epub 2014/01/15. doi: 10.1161/HYPERTENSIONAHA.113.02883 PMID: 24420551.
37. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001; 133(5): 687- 94. Epub 2001/06/29. doi: 10.1038/sj.bjp.0704131 PMID: 11429393; PubMed Central PMCID: PMC1572838.
38. Kanellakis P, Dinh TN, Agrotis A, Bobik A. CD4CD25Foxp3 regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens. 2011; 29(9):1820-8. Epub 2011/07/26. doi: 10.1097/HJH. 0b013e328349c62d PMID: 21785365.
39. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004; 64(22):8451-5. Epub 2004/11/19. doi: 10.1158/0008-5472.CAN-04-1987 PMID: 15548717.